Key result
Perioperative immunocorrection is proposed to enhance reparative response in ischemic myocardial microvascular dysfunction.
Why the study?
Modern treatments of coronary heart disease do not fully address impaired microcirculatory myocardial perfusion and microvascular dysfunction of the ischemic myocardium.
Pre- and postoperative immunocorrection is proposed to improve the outcomes of cell cardiomyoplasty and laser myocardial tunneling in patients with ischemic heart disease.
May support adjunctive microvascular strategies in CHD; leaves open durability and clinical translation of short-term effects.
Modern advances in the medical and surgical treatment of coronary heart disease (CHD), unfortunately, will not solve the entire arsenal of problems, associated with impaired microcirculatory myocardial perfusion. The proposed methods of influence on microvascular dysfunction of the ischemic myocardium, including cell cardiomyoplasty and laser myocardial tunneling, include a relatively short-lasting positive effect. For a more successful application of these modern approaches, an increase in the compensatory-reparative capabilities in these patients plays a significant role. A positive result of treatment, in this case, can be achieved by applying pre- and postoperative immunocorrection, since all these processes are immuno-conditioned.
No takes yet. Share an insight, caveat, or question.
Андриевских et al. (2019) conducted a review in Ischemic heart disease. Pre- and postoperative immunocorrection was evaluated. Pre- and postoperative immunocorrection is proposed to enhance the compensatory-reparative capabilities and prolong the effects of treatments for microvascular dysfunction in ischemic myocardium.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: